Taro Pharmaceutical Industries LTD. Ordinary Share (NYSE:TARO) had a decrease of its short interest by 4.75%. It was issued in November by FINRA the 563,900 short interest on TARO. That’s 4.75% down from 592,000 shares. Former TARO’s position will need 16 days to recover. It has 35,100 average volume. Taro Pharmaceutical Industries LTD. Ordinary Share float short is 5.7%.
TARO is hitting $103.43 during the last trading session, after decreased 1.20%.Taro Pharmaceutical Industries Ltd. has volume of 28,489 shares. Since November 10, 2017 TARO has declined 2.92% and is downtrending. TARO underperformed by 18.54% the S&P500.
Taro Pharmaceutical Industries Ltd., a science pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally.The firm is valued at $4.08 billion. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.The P/E ratio is 18.42. The firm sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies.
More recent Taro Pharmaceutical Industries Ltd. (NYSE:TARO) news were published by Businesswire.com, Streetinsider.com and Seekingalpha.com. The first one has “Taro Provides Results for September 30, 2018” as a title and was published on November 05, 2018. The next is “Taro Pharma (TARO) Misses Q2 EPS by 36c, Approves Special Dividend” on November 05, 2018. And last was published on November 06, 2018, called “Taro Pharmaceutical Industries Ltd (TARO) CEO Uday Baldota on 2018/19 First Half Results – Earnings Call Transcript”.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.